Ixico secures £3.5m Huntington's disease contract

(Sharecast News) - Ixico announced on Monday that it has secured a new £3.5m contract to provide imaging services for a global phase three clinical trial in Huntington's disease, marking a significant commercial win for the neuroscience-focused biomarker analytics group. The AIM-traded company said the agreement, signed with an unnamed global pharmaceutical partner, would run over four years and support research in a rare, hereditary neurodegenerative disorder that causes the progressive breakdown of nerve cells in the brain.

"This is an important contract in terms of value and trial stage that further cements Ixico's position in the field," said chief executive Bram Goorden.

"We are very proud to continue our support of the HD community, working with HD research consortia and pharmaceutical partners towards breakthrough treatments for patients in this devastating disease."

He added that he was "greatly encouraged by biopharma's increased commitment to invest in rare neurological diseases" and "optimistic this will lead to disease modifying solutions in the near future."

At 1504 GMT, shares in Ixico were up 5.12% at 11.3p.

Reporting by Josh White for Sharecast.com.